Motley Fool Premium
  1. Stocks
    2. /
  2. AstraZeneca Plc (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca Plc)

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Financial Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

AstraZeneca Plc (LSE: AZN) Latest News

Company Comment

Look No Further Than AstraZeneca plc For Growth And Income

| Mark Stones

AstraZeneca plc's (LON: AZN) impressive drugs pipeline and ambitious revenue targets make it my preferred pharma stock.

Read more »

Investing Articles

Why Is AstraZenenca plc So Expensive?

| Alan Oscroft

Why AstraZenenca plc (LON: AZN) shares are looking pricey.

Read more »

Investing Articles

AstraZeneca plc’s Not So Secret Weapon

| Rupert Hargreaves

AstraZeneca plc's (LON: AZN) CEO is committed to the company.

Read more »

Investing Articles

This Thing Could Put A Rocket Under AstraZeneca plc’s Shares

| G A Chester

AstraZeneca plc (LON:AZN) has 35% potential upside.

Read more »

Investing Articles

A New Bid For AstraZeneca plc In November?

| Alan Oscroft

Pfizer may be back for another tilt at AstraZenenca plc (LON: AZN).

Read more »

Investing Articles

Should I Invest In AstraZeneca Plc Now?

| Kevin Godbold

Can AstraZeneca plc (LON: AZN) still deliver a decent investment return?

Read more »

Company Comment

Is AstraZeneca plc A Buy On $45bn Revenue Targets?

| Mark Stones

Will AstraZeneca plc's (LON: AZN) drugs pipeline live up to expectations?

Read more »

Investing Articles

Why Is AstraZeneca plc Still Trading At A Premium To GlaxoSmithKline plc?

| Roland Head

Roland Head asks why AstraZeneca plc (LON:AZN) continues to trade at a premium to GlaxoSmithKline plc (LON:GSK), following the failed…

Read more »

Investing Videos

Neil Woodford Opens New Equity Income Fund

| Owain Bennallack

VIDEO: One Fool takes a look at Woodford's new fund.

Read more »

Company Comment

17% Annual Growth For The Next 7 Years?

| Maynard Paton

Sadly, few quoted companies ever issue specific sales guidance...

Read more »

Investing Articles

Why AstraZeneca plc Provides Poor Shareholder Value

| Royston Wild

Royston Wild looks at whether AstraZeneca plc (LON: AZN) is an attractive pick for value investors.

Read more »

Investing Articles

AstraZeneca plc Shows The Danger Of Buying On Takeover Talk

| Harvey Jones

Traders may have lost, but investors should ultimately win from holding AstraZeneca plc (LON: AZN), says Harvey Jones.

Read more »